keyword
MENU ▼
Read by QxMD icon Read
search

brain tumors pet

keyword
https://www.readbyqxmd.com/read/28536967/optimization-of-diagnostic-performance-for-differentiation-of-recurrence-from-radiation-necrosis-in-patients-with-metastatic-brain-tumors-using-tumor-volume-corrected-11-c-methionine-uptake
#1
Tae-Young Jung, In-Young Kim, Sa-Hoe Lim, Ki Seong Park, Dong-Yeon Kim, Shin Jung, Kyung-Sub Moon, Woo-Youl Jang, Sae-Ryung Kang, Sang-Geon Cho, Jung-Joon Min, Hee-Seung Bom, Seong Young Kwon
BACKGROUND: Tumor to normal tissue ratio (T/N ratio) on (11)C-methionine ((11)C-MET) positron emission tomography/computed tomography (PET/CT) is affected by variable factors. We investigated whether T/N ratio cutoff values corrected according to metabolic tumor volume (MTV) could improve the diagnostic performance of (11)C-MET PET/CT for diagnosis of recurrence in patients with metastatic brain tumor. Forty-eight patients with metastatic brain tumors underwent (11)C-MET PET/CT for differential diagnosis between recurrence and radiation necrosis after gamma knife radiosurgery (GKR)...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28534419/correlation-between-hypoxic-area-in-primary-brain-tumors-and-who-grade-differentiation-from-malignancy-using-18f-fluoromisonidazole-positron-emission-tomography
#2
Masafumi Kanoto, Kazukuni Kirii, Toshitada Hiraka, Yuuki Toyoguchi, Yukio Sugai, Kenichiro Matsuda, Kaori Sakurada, Yukihiko Sonoda, Jun Hatazawa, Takaaki Hosoya
Background 18F-fluoromisonidazole positron emission tomography (FMISO-PET) has been used for identification of hypoxic areas in tumors, and since hypoxia causes hypoxia-inducible factor-1 and enhancement of tumor growth, identifying the hypoxic area in the tumor tissue is important. Purpose To evaluate the usefulness of FMISO-PET in the grading of primary brain tumors. Material and Methods FMISO-PET was performed preoperatively on 41 consecutive patients with pathologically confirmed brain tumor. A neuroradiologist retrospectively measured both maximum standardized uptake value (SUVmax) and mean SUV (SUVmean) in the tumor and normal cerebellar parenchyma...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28527792/3d-cmro2-mapping-in-human-brain-with-direct-17-o-mri-comparison-of-conventional-and-proton-constrained-reconstructions
#3
Dmitry Kurzhunov, Robert Borowiak, Marco Reisert, Axel Joachim Krafft, Ali Caglar Özen, Michael Bock
Oxygen metabolism is altered in brain tumor regions and is quantified by the cerebral metabolic rate of oxygen consumption (CMRO2). Direct dynamic (17)O MRI with inhalation of isotopically enriched (17)O2 gas can be used to quantify CMRO2; however, pixel-wise CMRO2 quantification in human brain is challenging due to low natural abundance of (17)O isotope and, thus, the low signal-to-noise ratio (SNR) of (17)O MR images. To test the feasibility CMRO2 mapping at a clinical 3 T MRI system, a new iterative reconstruction was proposed, which uses the edge information contained in a co-registered (1)H gradient image to construct a non-homogeneous anisotropic diffusion (AD) filter...
May 17, 2017: NeuroImage
https://www.readbyqxmd.com/read/28521439/arteriovenous-malformation-and-thyroid-metastasis-from-underlying-renal-cell-carcinoma-an-unusual-presentation-of-malignancy-a-case-report
#4
H J Albandar, E S Roberto, J R H See, J H Sabiers
Renal Clear Cell Carcinoma (RCC) comprises over 80% of renal malignancies in adults. Thyroid gland metastasis is rare in RCC. Few studies have described cases of RCC mistaken for benign arteriovenous malformation (AVM). To the best of our knowledge, an AVM arising from underlying RCC metastasis to the brain has not yet been reported. The current study presents a case of RCC metastasis to the thyroid gland, with an AVM identified to be a result of metastatic involvement in the brain. A 45-year-old African-American female presented with left-sided weakness, slurred speech, facial droop and seizure...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28495911/intratumoral-injection-of-hsv1716-an-oncolytic-herpes-virus-is-safe-and-shows-evidence-of-immune-response-and-viral-replication-in-young-cancer-patients
#5
Keri A Streby, James I Geller, Mark A Currier, Patrick S Warren, John M Racadio, Alexander J Towbin, Michele R Vaughan, Melinda Triplet, Kristy Ott-Napier, Devon J Dishman, Lori R Backus, Beth Stockman, Marianne Brunner, Kathleen Simpson, Robert Spavin, Joe Conner, Timothy P Cripe
Purpose: HSV1716 is an oncolytic herpes simplex virus-1 (HSV-1) studied in adults via injection into the brain and superficial tumors. To determine the safety of administering HSV1716 to pediatric patients with cancer, we conducted a phase I trial of image-guided injection in young patients with relapsed or refractory extracranial cancers.Experimental Design: We delivered a single dose of 10(5) to 10(7) infectious units of HSV1716 via computed tomography-guided intratumoral injection and measured tumor responses by imaging...
May 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28495008/a-fully-automatic-approach-for-multimodal-pet-and-mr-image-segmentation-in-gamma-knife-treatment-planning
#6
Leonardo Rundo, Alessandro Stefano, Carmelo Militello, Giorgio Russo, Maria Gabriella Sabini, Corrado D'Arrigo, Francesco Marletta, Massimo Ippolito, Giancarlo Mauri, Salvatore Vitabile, Maria Carla Gilardi
BACKGROUND AND OBJECTIVES: Nowadays, clinical practice in Gamma Knife treatments is generally based on MRI anatomical information alone. However, the joint use of MRI and PET images can be useful for considering both anatomical and metabolic information about the lesion to be treated. In this paper we present a co-segmentation method to integrate the segmented Biological Target Volume (BTV), using [(11)C]-Methionine-PET (MET-PET) images, and the segmented Gross Target Volume (GTV), on the respective co-registered MR images...
June 2017: Computer Methods and Programs in Biomedicine
https://www.readbyqxmd.com/read/28493046/trastuzumab-uptake-and-its-relation-to-efficacy-in-an-animal-model-of-her2-positive-breast-cancer-brain-metastasis
#7
Gail D Lewis Phillips, Merry C Nishimura, Jennifer Arca Lacap, Samir Kharbanda, Elaine Mai, Janet Tien, Kimberly Malesky, Simon P Williams, Jan Marik, Heidi S Phillips
PURPOSE: The extent to which efficacy of the HER2 antibody Trastuzumab in brain metastases is limited by access of antibody to brain lesions remains a question of significant clinical importance. We investigated the uptake and distribution of trastuzumab in brain and mammary fat pad grafts of HER2-positive breast cancer to evaluate the relationship of these parameters to the anti-tumor activity of trastuzumab and trastuzumab emtansine (T-DM1). METHODS: Mouse transgenic breast tumor cells expressing human HER2 (Fo2-1282 or Fo5) were used to establish intracranial and orthotopic tumors...
May 10, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28479199/radiosynthesis-and-evaluation-of-igf1r-pet-ligand-11-c-gsk1838705a
#8
Kiran Kumar Solingapuram Sai, Jaya Prabhakaran, Anirudh Sattiraju, J John Mann, Akiva Mintz, J S Dileep Kumar
Radiosynthesis and evaluation of [(11)C]GSK1838705A in mice using microPET and determination of specificity in human GBM UG87MR cells are described herein. The radioligand was synthesized by reacting desmethyl-GSK1838705A with [(11)C]CH3I using GE FX2MeI module in ∼5% yield (EOS), >95% radiochemical purity and a specific activity of 2.5±0.5Ci/μmol. MicroPET imaging in mice indicated that [(11)C]GSK1838705A penetrated blood brain barrier (BBB) and showed retention of radiotracer in brain. The radioligand exhibited high uptake in U87MG cells with >70% specific binding to IGF1R...
April 27, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28468949/identification-of-a-novel-the-itg%C3%AE-v%C3%AE-6-binding-peptide-using-protein-separation-and-phage-display
#9
Uwe Haberkorn, Annette Altmann, Max Sauter, Saskia Roesch, Walter Mier, Rolf Warta, Juergen Debus, Gerhard Dyckhoff, Christel Herold-Mende
PURPOSE: Targeted therapies are regarded as promising approaches to increase 5-year survival rate of head and neck squamous cell carcinoma (HNSCC) patients. EXPERIMENTAL DESIGN: For the selection of carcinoma-specific peptides membrane proteome of HNO97 tumor cells fractionated by the ProteomeLab™ PF2D system and corresponding HNO97 cells were deployed for an alternating biopanning using a sunflower trypsin inhibitor1-based phage display (SFTI8Ph) library. Stability, binding properties and affinity of novel candidates were assessed in vitro using radio-HPLC, binding experiments and surface plasmon resonance assay (SPR), respectively...
May 3, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28464742/functional-image-guided-dose-escalation-in-gliomas-using-of-state-of-the-art-photon-vs-proton-therapy
#10
Anne Ivalu Sander Holm, Jørgen Breede Baltzer Petersen, Ludvig Paul Muren, Klaus Seiersen, Per Borghammer, Slávka Lukacova
BACKGROUND: Recurrences of glioma are usually local, suggesting the need for higher tumor dose. We investigated the boundaries for dose escalation of an (18)F-fluoro-ethyl-tyrosine positron emission tomography defined target by intensity-modulated photon therapy (IMRT), volumetric modulated arc therapy (VMAT) and intensity-modulated proton therapy (IMPT). MATERIALS AND METHODS: Standard dose (60 Gy) and dose-escalated plans were calculated for seven patients using IMRT, VMAT and IMPT...
June 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28458384/clinical-utility-of-positron-emission-tomography-in-patients-with-malignant-glioma
#11
Hirohito Yano, Jun Shinoda, Toru Iwama
Positron emission tomography (PET) is being increasingly utilized for the management of brain tumors. Herein, we primarily review our previous studies on the use of PET in glioma that utilize three types of tracers: (11)C-methionine (MET), (11)C-choline, and (18)F-fluorodeoxyglucose. These studies included aspects such as tumor behavior, diagnosis, grade of malignancy, spread and invasion, viability, and genetic deletions; moreover, they also evaluated PET as a tool for planning radiation therapy (RT) and determining its outcome...
May 1, 2017: Neurologia Medico-chirurgica
https://www.readbyqxmd.com/read/28456080/radiosynthesis-and-biological-evaluation-of-n-2-18-f-fluoropropionyl-3-4-dihydroxy-l-phenylalanine-as-a-pet-tracer-for-oncologic-imaging
#12
Caihua Tang, Dahong Nie, Ganghua Tang, Siyuan Gao, Shaoyu Liu, Fuhua Wen, Xiaolan Tang
INTRODUCTION: Several (11)C and (18)F labeled 3,4-dihydroxy-l-phenylalanine (l-DOPA) analogues have been used for neurologic and oncologic diseases, especially for brain tumors and neuroendocrine tumors PET imaging. However, (18)F-labeled N-substituted l-DOPA analogues have not been reported so far. In the current study, radiosynthesis and biological evaluation of a new (18)F-labeled l-DOPA analogue, N-(2-[(18)F]fluoropropionyl)-3,4-dihydroxy-l-phenylalanine ([(18)F]FPDOPA) for tumor PET imaging are performed...
April 7, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28441783/comparison-between-mr-perfusion-and-18f-fdg-pet-in-differentiating-tumor-recurrence-from-nonneoplastic-contrast-enhancing-tissue
#13
Yogesh Kumar, Nishant Gupta, Manisha Mangla, Kusum Hooda, Rajiv Mangla
Objective: Comparison of the accuracy of MR perfusion and 18-FDG-PET for differentiating tumor progression from nonneoplastic contrast-enhancing tissue. Methods and Materials: Retrospective review of MR perfusion and 18-FDG-PET in 23 cases of primary brain tumors (17 high grade and 6 low grade glial neoplasms) and 5 cases of metastatic lesions with enhancing lesions on post-treatment MRI was performed. The accuracy of MR perfusion versus 18-FDG-PET for distinguishing between nonneoplastic contrast-enhancing tissue and tumor recurrence was assessed...
March 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28439843/effective-dose-estimation-for-oncological-and-neurological-pet-ct-procedures
#14
Josep M Martí-Climent, Elena Prieto, Verónica Morán, Lidia Sancho, Macarena Rodríguez-Fraile, Javier Arbizu, María J García-Velloso, José A Richter
BACKGROUND: The aim of this study was to retrospectively evaluate the patient effective dose (ED) for different PET/CT procedures performed with a variety of PET radiopharmaceutical compounds. PET/CT studies of 210 patients were reviewed including Torso (n = 123), Whole body (WB) (n = 36), Head and Neck Tumor (HNT) (n = 10), and Brain (n = 41) protocols with (18)FDG (n = 170), (11)C-CHOL (n = 10), (18)FDOPA (n = 10), (11)C-MET (n = 10), and (18)F-florbetapir (n = 10)...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28439784/practical-calculation-method-to-estimate-the-absolute-boron-concentration-in-tissues-using-18-f-fbpa-pet
#15
Tadashi Watabe, Kohei Hanaoka, Sadahiro Naka, Yasukazu Kanai, Hayato Ikeda, Masanao Aoki, Eku Shimosegawa, Mitsunori Kirihata, Jun Hatazawa
PURPOSE: The purpose of this study was to establish a practical method to estimate the absolute boron concentrations in the tissues based on the standardized uptake values (SUVs) after administration of 4-borono-phenylalanine (BPA) using 4-borono-2-(18)F-fluoro-phenylalanine ((18)F-FBPA) PET. METHODS: Rat xenograft models of C6 glioma (n = 7, body weight 241 ± 28.0 g) were used for the study. PET was performed 60 min after intravenous injection of (18)F-FBPA (30...
April 24, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28425764/braf-v600e-mutant-papillary-craniopharyngioma-dramatically-responds-to-combination-braf-and-mek-inhibitors
#16
Ashley Roque, Yazmin Odia
We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28422499/development-of-a-18-f-labeled-radiotracer-with-improved-brain-kinetics-for-positron-emission-tomography-imaging-of-translocator-protein-18-kda-in-ischemic-brain-and-glioma
#17
Masayuki Fujinaga, Rui Luo, Katsushi Kumata, Yiding Zhang, Akiko Hatori, Tomoteru Yamasaki, Lin Xie, Wakana Mori, Yusuke Kurihara, Masanao Ogawa, Nobuki Nengaki, Feng Wang, Ming-Rong Zhang
We designed four novel acetamidobenzoxazolone compounds 7a-d as candidates for positron emission tomography (PET) radiotracers for imaging the translocator protein (18 kDa, TSPO) in ischemic brain and glioma. Among these compounds, 2-(5-(6-fluoropyridin-3-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)-N-methyl-N-phenylacetamide (7d) exhibited high binding affinity (Ki = 13.4 nM) with the TSPO and moderate lipophilicity (log D = 1.92). [(18)F]7d was radiosynthesized by [(18)F]fluorination of the bromopyridine precursor 7h with [(18)F]F(-) in 12 ± 5% radiochemical yield (n = 6, decay-corrected)...
May 11, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28421396/-11-c-methionine-pet-ct-findings-in-benign-brain-disease
#18
REVIEW
Reiko Nakajima, Ken Kimura, Koichiro Abe, Shuji Sakai
(11)C-methionine (MET) is one of the most commonly used positron emission tomography (PET) tracers for evaluation of malignant brain tumor, with MET-PET being a sensitive technique for visualization of primary and recurrent malignant brain tumors. However, previous reports have demonstrated MET uptake in lesions associated with benign brain diseases. These diseases usually show an increase in MET uptake similar to that of malignant tumors. This pitfall in MET-PET image interpretation is important not only for nuclear medicine professionals, but also for radiologists...
April 18, 2017: Japanese Journal of Radiology
https://www.readbyqxmd.com/read/28419645/diagnostic-performance-of-different-imaging-modalities-in-the-assessment-of-distant-metastasis-and-local-recurrence-of-tumor-in-patients-with-non-small-cell-lung-cancer
#19
Yoshiharu Ohno, Takeshi Yoshikawa, Yuji Kishida, Shinichiro Seki, Hisanobu Koyama, Masao Yui, Yoshimori Kassai, Kota Aoyagi, Shigeo Kaminaga, Kazuro Sugimura
PURPOSE: To compare the diagnostic performance of positron emission tomography with [18F] fluoro-2-deoxy-glucose (FDG-PET) coregistered with magnetic resonance imaging (FDG-PET/MRI), MRI with and without diffusion-weighted imaging (DWI), FDG-PET fused with computed tomography (FDG-PET/CT) with brain contrast-enhanced (CE-) MRI, and routine radiological examination for assessment of postoperative recurrence in nonsmall-cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: 96 consecutive postoperative NSCLC patients (52 men, 44 women; mean age 72 years) prospectively underwent whole-body 3T MRI with and without DWI; PET/CTs and routine radiological examinations consisted of CE-brain MRI, whole-body CE-CT, and bone scintigraphy...
April 17, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28415059/-a-case-of-slowly-progressive-brain-metastasis-with-minor-bleeding-after-removal-of-and-chemotherapy-for-non-small-cell-lung-cancer
#20
Hiroshi Matsufuji, Eri Shiozaki, Yasutaka Nakatake, Koichi Yoshida, Kensaku Kamada, Takayuki Matsuo
Of all brain metastases, the most common primary lesion is derived from the lung. These types of metastases enlarge aggressively with unfavorable prognoses. We report the case of a 75-year-old male patient who had a history of pulmonary resection for Stage IA non-small cell lung cancer(NSCLC), and received chemotherapy. One year after NSCLC surgery, he experienced a cardiogenic cerebral infarction, and anticoagulant therapy was initiated. Mass lesions with hemorrhage were detected bilaterally in the frontal lobes through magnetic resonance imaging three years after the NSCLC surgery...
April 2017: No Shinkei Geka. Neurological Surgery
keyword
keyword
84290
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"